Our previous studies demonstrated coordinate ex pression of platelet-derived growth factor (PDGF) -B chain and (3-receptor in neurons at risk in the rat brain with focal isch emia, To clarify a role of the -B chain in the brain further, we examined whether PDGF-A or -B chain protects CA I pyrami dal neurons from delayed neuronal death after forebrain isch emia in rats. Pretreatment with PDGF-BB, but not -AA, at 120 ng/d for 2 days until forebrain ischemia was performed mark edly ameliorated delayed neuronal death in CA I pyramidal neurons on da i 7 after ischemia. This neuroprotective effect of
PDGF-BB was dose-dependent, and pretreatment with PDGF BB at 240 ng/d showed almost complete inhibition of delayed neuronal death. In contrast, posttreatment with PDGF-BB at 120 ng/d starting 20 minutes after ischemia demonstrated no significant neuroprotecti ve effect. The current study established marked neuroprotective actions of PDGF-BB in ischemic neu ronal damage. Key Words: Cerebral ischemia-Delayed neu ronal death-Hippocampus-Neuroprotection-Neurotrophic factor-Platelet-derived growth factor (pDGF).
-B chain, whereas the [3 subunit can bind only to the -B chain (Hart et a!., 1988; Heldin et a!., 1988; Matsui et a!., 1989; Seifert et a!., 1989) .
Tn the central nervous system, the PDGF-A chain was shown to play an important role in the proliferation and programed differentiation of oligodendrocyte-type 2 as trocyte progenitor cells of the glial lineage Raff et a!., 1988) . However, it was shown recently that both PDGF-A and -B chains are present in neuronal cells in the developing and mature central nervous sys tem, suggesting a crucial role of PDGF as a neuronal regulatory agent (Sasahara et a!., 1991; Yeh et a!., 1991; Sasahara et a!., 1992; Hutchins and Jefferson, 1992) . Tn addition, both PDGF a-and [3-receptor mRNAs were shown to be widely expressed in the brain (Sasahara et a!., 1991) . The a-receptor mRNA in the brain was found to be expressed largely in glial cells during development in the mouse and rat (Pringle et a!., 1992; Yeh et a!., 1993) . The [3-receptor is expressed at high levels in the mouse forebrain during embryonic and early postnatal development (Hutchins and Jefferson, 1992) . A previous study showed that PDGF-B chain has trophic activity on cultured neurons through binding to the [3-receptor (Smits et a!., 1991) . Taken together, these observations suggest that PDGFs may affect not only glial cells but also neurons through binding to their high affinity recep-tors on these cells mainly during the embryonic and early postnatal development of the brain. However, the roles of PDGFs, especially in the mature brain, remain un known.
Recently, we have shown that ischemia enhances ex pression of -B chain mRNA and increases -B chain im munoreactivity in neurons and brain macrophages in the focal ischemia model in the rat brain (Iihara et aI., 1993 (Iihara et aI., , 1994 . In contrast, PDGF-A chain mRNA expression re mains unchanged in the ischemic brain, suggesting an important role of the -B chain in the ischemic brain (Iihara et aI., 1994) . Furthermore, the expression of PDGF l3-receptor, which is specific to the -B chain, was found to increase in the ischemic brain, supporting the hypothesis that PDGF-B chain may play a crucial role in the cellular cascade of the healing process in the isch emic brain, including survival of neurons at risk, glial response, accumulation of brain macrophages, and neo vascularization (Iihara et aI., 1996a) . The present study was designed to determine whether PDGFs can rescue the delayed neuronal death after transient forebrain isch emia in rats. Preliminary results of this study were pub lished previously in abstract form (lihara et aI., 1996b) .
MATERIALS AND METHODS

Induction df forebrain ischemia
Male Wistar rats, weighing 180 to 220 g, were used for the experiments. The animals were starved during the night pre ceding the induction of forebrain ischemia but were allowed water ad libitum. Transient forebrain ischemia was induced according to the method reported by Smith et al. (1984) with some modifications (Kaku et aI., 1993) . Briefly, rats were anes thetized with 3.5% halothane, intubated, and connected to a Starling-type respirator. Anesthesia was maintained with 0.7'/'0 halothane and 30% O2 in N20. The femoral artery and vein were exposed to insert polyethylene catheters for monitoring arterial blood pressure, arterial blood gases, and blood glucose level. After isolation of the bilateral common carotid arteries, halothane was discontinued and the rats were allowed to remain in a steady state for a period of 20 minutes, with the rectal temperature at 37°C, Pa02 at 120 to 140 mm Hg, and Paco2 at 30 to 40 mm Hg. Transient forebrain ischemia was induced by clamping the carotid arteries bilaterally and lowering the blood pressure to 50 mm Hg for 8 minutes by administering trimeth aphan camphor sulfonate and withdrawing blood from the ve nous catheter. After the 8-minute period of ischemia, blood pressure was restored by rapid reinfusion of the shed blood and the bilateral carotid clamps were removed. After surgery, the rats were housed in cages under controlled lighting and envi ronmental conditions (22 ± 2°C, 70 ± 15% humidity).
Reproducibility of delayed neuronal death in the pyramidal neurons in CA I subfield was examined in rats (n = 7) sub jected to transient forebrain ischemia alone without implanta tion of an osmotic mini pump. 200-fLL fill volume, 0.5-fLLIh pump rate, Alza Corp., Palo Alto, CA) contained (I) bovine serum albumin (BSA, Fraction Y, Sigma Chemical Co., St. Louis, MO, U.S.A.) as a control, (II) recombinant human PDGF-AA (Oncogene Science), or (III) recombinant human PDGF-BB (Oncogene Science). In each group, the minipump contained 2 fLg of the respective agent, dissolved in 200 fLl of artificial CSF that had been pre pared in a sterile, pyrogen-free water.
The rats were anesthetized with pentobarbital sodium (50 mg/kg intraperitoneally) and placed in a stereotactic head holder. The coordinates of stereotactic puncture into the right lateral ventricle were set as 0.8 mm posterior to the bregma, 1.5 mm right of the midline, and 4.3 mm beneath the surface of the skull. The inserted 29-gauge stainless steel intraventricular can nula was fixed to the skull with bone cement and connected to a polyethylene tube. The osmotic minipump was implanted subcutaneously in the neck and connected to the tube. At the concentration and pump rate used, BSA, PDGF-AA, or PDGF BB were delivered at a dose of 120 ng/d into the right lateral ventricles of normothermic rats until the transient forebrain ischemia procedure was performed.
Two days after beginning the infusion, rats were subjected to transient forebrain ischemia as described (Kaku et aI., 1993) after removal of the intraventricular cannula.
On day 7 after ischemia, the rats were deeply anesthetized with pentobarbital, and perfused transcardially with 0.05 mollL phosphate-buffered saline at pH 7.4 and then with 2% para formaldehyde in the same buffer. The perfused brain was dis sected out, cut into coronal slices 5-mm thick at the level of the dorsal hippocampus, and incubated in the same fixative over night. Frozen coronal sections 20-fLm thick were then prepared and stained with hematoxylin and eosin. Under the light mi croscope at a magnification of x400, the numbers of surviving pyramidal neurons in the center of the right CA I subfield per I mm were counted. All cell counting was done blind with re spect to experimental groups.
The numbers of the surviving pyramidal neurons and physi ologic parameters in the PDGF-AA or -BB-treated groups were compared with those of rats subjected to continuous infusion of BSA (Control) with the ischemic procedure (n = 7 each).
Experiment 2. Dose-response analysis of the neuroprotective effects of pretreatment with PDGF -AA or BB on delayed neuronal death after forebrain ischemia Platelet-derived growth factor-AA or -BB at a dose of 60 or 240 ng/d were infused intracerebroventricularly for 2 days until the onset of the transient forebrain ischemia procedure in nor mothermic rats as described in experiment I (n = 7 each). Direct visual counting of the surviving CA 1 pyramidal neurons was performed under a microscope. All cell counting was done blind with respect to experimental groups. Control animals re ceived continuous intracerebroventricular infusion of BSA. Male Wi star rats (n = 7) weighing 180 to 220 g were sub jected to transient forebrain ischemia after overnight fasting as described above. Twenty minutes after cessation of forebrain ischemia, rats were placed in a stereotactic head holder and subjected to continuous intracerebroventricular infusion of PDGF-BB as described above (120 ng/mL) until day 7 after ischemia. On day 7, rats were sacrificed under deep anesthesia, and the numbers of pyramidal neurons per 1 mm in the center of CA 1 subfield were counted. All cell counting was done blind with respect to experimental groups. Control rats (n = 7) were subjected to transient forebrain ischemia with continuous in tracerebroventricular infusion of BSA (120 ng/mL) otherwise in the same procedure.
Immunostaining for glial fibrillary acidic protein
To examine the involvement of glial cells in the neuropro tective actions of PDGF-BB, immunostaining for glial fibrillary acidic protein (GFAP) was done on the coronal section at the level of insertion of the catheters in groups that had been sub jected to contirtuous infusion of PDGF-AA or -BB for 2 days (120 ng/mL; n = 3 each) without induction of transient fore brain ischemia. Glial fibrillary acidic protein immunostaining WaS done as described in our previous paper (Iihara et aI., 1996a) . The numbers of GFAP-positive cells around the site of insertion of the catheters into the ventricle was counted in the high-power field under microscope.
Statistical analysis
Data are expressed as means ± SD. The significance of the results was tested with one-way analysis of variance followed by Fisher's protected least significance difference for multiple comparisons between groups. Differences were considered sta tistically significant when the P value was < 0.05.
RESULTS
Physiologic parameters, including blood glucose lev els, arterial pH, P a02' P aco2' and rectal temperature, showed no significant differences between groups in each experiment (Table I) . Reproducibility of delayed neuronal death in the CA I subfield in the hippocampus was confirmed in rats subjected to transient forebrain ischemia without placement of the minipumps (n = 7) (Figs. IB and 2B). This ischemic procedure induced de layed neuronal death in CA I subfield as reported previ ously, and the neuronal density was 23.2 ± 5.I/mm (nor mal control; 401 ± 22.8/mm; n = 7).
Pretreatment with PDGF-AA at 120 ng/d showed no significant neuroprotective effects against delayed neu ronal death in the CA 1 subfield as compared with the BSA group. The numbers of pyramidal neurons in the hippocampal CA 1 subfields on day 7 were 46. I ± 7.3/ mm and 53 ± 5.9/mm, respectively (Figs. IC, ID, 2C, and 2D). In contrast, PDGF-BB at a dose of 120 ng/d markedly ameliorated delayed neuronal death in the CAl pyramidal neurons in the right hippocampus on day 7 after ischemia (252.8 ± 78.7/mm; n = 7, P < 0.001 vs. BSA-treated animals) (Figs. IE and 2E) . This reduction in neuronal death was confined to the hippocampus ip silateral to the ventricular infusion, and no significant increase was observed in the numbers of surviving CAl pyramidal neurons in the left hippocampus (Figs. I F and 2F).
Three different concentrations of PDGF-AA or PDGF-BB were tested and significant increases in sur vival of CAl pyramidal neurons were seen by pretreat ment with PDGF-BB at doses of 120 and 240 ng/d (252.8 ± 78.7/mm; n = 7, P < 0.001; 354.5 ± 36.0/mm; n = 7, P < 0.001; respectively vs. BSA-treated animals) (Figs. 3A and 4). The most pronounced reduction of neuronal death was observed at a dose of 240 ng/d, and adminis tration of PDGF-BB at this dose showed almost com plete inhibition of delayed neuronal death in the CA 1 pyramidal neurons in the right hippocampus on day 7 after ischemia (354.5 ± 36.0/mm, n = 7) ( Fig. 3A ). Even at this dose, the neuroprotective effect was seen only in the right hippocampus (data not shown). On the other hand, no significant reduction in neuronal death was found by pretreatment with PDGF-AA at doses up to 240 ng/d (Fig. 4) .
The effects of PDGF-BB at 120 ng/d on the delayed neuronal death were also tested in rats subjected to post treatment from 20 minutes until day 7 after ischemia. No significant increase in the survival of CAl pyramidal neurons was observed on day 7 after ischemia at this dose of PDGF-BB (54.0 ± 24.0/mm, n = 7) as compared with BSA (53.0 ± 5.9/mm, n = 7) ( Figs. 3B and 4) .
The immunostaining for GFAP in the rats that had been infused continuously for 2 days (120 ng/d) showed no significant difference of GFAP-positive cells in the vicinity of the ventricular wall that had been penetrated by the catheters (Fig. 5) 
DISCUSSION
The present study demonstrated that pretreatment with PDGF-BB, but not PDGF-AA, showed a marked neuro protective effect against delayed neuronal death of pyra-J Cereb Blood Flow Metah. Va!. 17. No. 10. 1997 midal neurons in the CAl subfield after forebrain isch emia in rats. This neuroprotective effect was dose dependent, and almost complete inhibition of delayed neuronal death was seen at a dose of 240 ng/d for 2 days before ischemia. However, no such reduction in neuronal death was observed by posttreatment with PDGF-BB.
Recently, several neurotrophic or growth factors, such as nerve growth factor (NGF), brain-derived neuro- trophic factor, acidic and basic fibroblast growth factors, and ciliary neurotrophic factors, have been reported to reduce delayed neuronal death after transient forebrain ischemia in rodents (Shigeno et a!., 1991; Yamamoto et aI., 1992; Sasaki et aI., 1992; Nakata et aI., 1993; Tsu kahara et aI., 1994; Beck et aI., 1994; Wen et aI., 1995) . In contrast, other groups reported no neuroprotective ef fects of these factors (Hara et aI., 1991; Beck et aI., 1992) . These inconsistent results may be explained by differences in dose, rate, and timing of infusion used in these studies (Yamamoto et aI., 1992) .
The dose and rate of infusion chosen in the present study were similar to those in some previous studies using acidic and basic fibroblast growth factors, and cili ary neurotrophic factor (240 ng/d, 240 ng/d, and 50-500 ng/d, respectively, continuous intraventricular infusion) (Sasaki et a!., 1992; Nakata et aI., 1993; Wen et aI., 1995) , but much less than in another study using NGF (lO f.Lg bolus, intraventricular injection) (Shigeno et aI., 1991) . In the present study, significant neuroprotection with PDGF-BB was found to be limited to the hippo campus on the side ipsilateral to the ventricular infusion. The reason for this lack of neuroprotection in the con tralateral hippocampus remains unknown, but may be explained by the lower concentration of the factor in the contralateral ventricle or by the more limited diffusion into the hippocampus in the hemisphere not injured by placement of the catheter. At the present time, it is un clear how far PDGF is capable of diffusing through trau matized or nontraumatized brains. In case of intraven tricular infusion of NGF, some studies indicated that NGF can diffuse through the brain as little as 1 mm (Lapchak et aI., 1993) , whereas other studies reported specific uptake and transport of NGF to basal forebrain cholinergic system in nonhuman primate (Emmet et aI., 1994) . It was also reported that there was a good corre lation between the infused NGF labeling pattern and the presence of trk A NGF receptors (Lapchak et a\., 1993) . Platelet-derived growth factor, infused into the ventricle, seems to reach the contralateral ventricle as rapidly as is J Cereb Blood Flow Metab. Vol. 17, No. 10, 1997 reported for NGF (Lapchak et a!., 1993) . On the other hand, our previous studies demonstrated enhanced im munoreactivity for PDGF l3-receptor in the neurons at risk and reactive glial cells in the vicinity of infarct and stab wound in the rat brain (Iihara et aI., 1996a: Iihara et aI., unpublished observation) . Taken together, these stud ies suggest that the increased expression and altered lo calization of PDGF receptor after insertion of the cath eter might have changed the uptake mechanism and ac cumulation of infused PDGF. To conclude definitely on this issue and determine the ideal dose and rate of infu sion of PDGF-BB, more studies are necessary on their uptake mechanisms, time course of intraventricular and intrahippocampal concentration of PDGF, and the expression of PDGF receptors after the ventricular infusion.
Our results demonstrated no neuroprotective effects by posttreatment with PDGF-BB beginning 20 minutes after ischemia at the concentration employed (120 ng/d). In contrast, some previous studies reported a neuropro tective effect on delayed neuronal death after forebrain ischemia by posttreatment with a single bolus injection of a much higher dose of NGF (lO f.Lg) at 15 minutes after ischemia (Shigeno et aI., 1991) or with delayed continuous infusion of acidic fibroblast growth factor, starting earlier (5 minutes) after ischemia (Sasaki et a!., 1992) as compared with the current study. Ginsberg (1995) suggested that there may be a continuum of thera peutic benefit of a given agent such that the extent of benefit diminishes gradually as the time to initiation is prolonged and the intensity of treatment decreases. Be cause these neurotrophic or growth factors share some neuroprotective actions on the cascade of events elicited after ischemic insult as discussed below, delayed and insufficient increases in the intraventricular concentra tion of PDGF-BB at the dose used in the present study may account for the lack of effects against delayed neu ronal death. An alternative explanation for the lack of effect of posttreatment with PDGF-BB is that the sus tained inhibition of protein synthesis after global isch emia (Thilmann et a!., 1986; Widmann et aI., 1991) may preclude de novo translation of essential, neuroprotective proteins induced by PDGF, although at least some pro teins, such as several immediate early gene (Jorgensen et aI., 1991; Neumann-Haefelin et aI., 1994) and heat shock proteins (Chopp et aI., 1991; Deshpande et aI., 1992) , can be synthesized in the vulnerable regions, such as the CA 1 region, after ischemia. This view is consistant with the previous study that showed that the neuroprotective ac tions of basic fibroblast growth factor against excitotox icity require new protein synthesis (Mattson et aI., 1989 ).
The precise mechanisms underlying neuroprotection by neurotrophic or growth factors against delayed neu ronal death remain unknown. Three major hypotheses have been postulated for the occurrence of delayed neu- Bar graph showing dose-dependency of neuroprotective actions of pretreatment with PDGF-BB against delayed neuronal death in the pyramidal neurons in the CA 1 subfield. Significant and dose-dependent neuroprotective actions were observed in the groups subjected to pretreatment with PDGF-BB at doses of 120 and 240 ng/d for 2 days until ischemia (one-way analysis of variance followed by Fisher's protected least significance difference [PLSD] ). In contrast, neither pretreatment with PDGF-AA at doses up to 240 ng/d or posttreatment with PDGF-BB (120 ng/d) showed significant neuroprotective effects. Data are expressed as mean ± SD (n = 7 each). BSA, bovine serum albumin; N.S., not significant. ronal death after forebrain ischemia: (I) persisting de pression of protein synthesis that precludes long-term survival (Thilmann et aI., 1986; Widmann et aI., 1991) ;
(2) perturbed signal-transduction pathway that includes imbalance in the activation of growth factors and gluta mate receptors (Mattson et a!., 1989) and between pro tein kinase and phosphatases (Saitoh et aI., 1991; Wieloch et aI., 1993) ; and (3) sustained perturbation of cell calcium metabolism (Deshpande et a!., 1987; Siesjo, 1991) . Several lines of evidence have demonstrated that neurotrophic or growth factors antagonize neurotoxicity caused by glutamate (Mattson et a!., 1989; Frim et a!., 1993) or nitric oxide (Maiese et a!., 1993) and reduce neuronal death after hypoxia or glucose-deprivation in jury (Cheng and Mattson, 199 1) . In addition, these fac tors maintain calcium homeostasis in neurons at risk by inducing calcium-binding proteins, such as calbindin (Cheng and Mattson, 1991; Collazo et aI., 1992; Cheng and Mattson, 1994) , and reduce oxidant injury by induc ing antioxidant enzymes, such as Cu-Zn superoxide dis mutase, catalase, and glutathione peroxidase (Pan and Perez-Polo, 1993; Zhang et aI., 1993; Goodman and Mattson, 1994; Cheng and Mattson, 1995) .
Another important point to consider is whether marked neuroprotective action of PDGF-BB is directly exerted on neurons or indirectly mediated by stimulation of glial cells. Our finding of no significant difference in the number of glial cells on the day of ischemia between PDGF-AA and -BB groups in this study may favor the idea that PDGF-BB exerts its trophic action directly on neurons that possess PDGF [j-receptors as described be low.
Platelet-derived growth factor-BB was also shown to exert trophic activity on neurons both in vitro and in vivo. Platelet-derived growth factor-BB prolongs the survival and induces neurite outgrowth of cultured rat brain neu rons through binding to functional PDGF [j-receptors on these cells (Smits et aI., 199 1) . This neurotrophic activity has also been demonstrated on cultured mesencephalic dopaminergic neurons (Nikkhah et aI., 1993) and cer ebellar 'Y-aminobutyric acid interneurons (Smits et aI., \993) . Recently, it was reported that a brief activation of PDGF-[j receptor by PDGF-BB produces a long-lasting inhibition of N-methyl-o-aspartate (NMDA) -dependent excitatory postsynaptic currents in CA 1 pyramidal neu rons in rat hippocampal slices (Valenzuela et aI., 1996) . This study also demonstrated that PDGF inhibited NMDA receptors in cultured hippocampal neurons by a mechanism that involves a decrease in single channel open probability. Taken together, this study raises a pos sibility that PDGF-BB might prevent delayed neuronal death after ischemia by inhibiting Ca 2 + influx by NMDA receptors, although variable results on the effect of NMDA antagonists have been reported in global isch emia (Albers et a!., 1992) .
In addition, PDGF-BB protects cultured hippocampal neurons against injury caused by glucose deprivation when added before or up to 8 hours after the insult (Cheng and Mattson, 1995) . In the case of FeS04induced oxidant injury, pretreatment with PDGF-AA or -BB is required to protect the neurons by inducing anti oxidant enzymes. This study demonstrated that both PDGF-AA and -BB showed similar neuroprotective ac tions in each injury paradigm (Cheng and Mattson, 1995) . In the current study, however, the potent neuro protective actions of PDGF-BB against delayed neuronal death were in marked contrast to the lack of significant effects of PDGF-AA. This inconsistency might have been because hippocampal neurons in the adult rat brain express only PDGF-� receptor in vivo, which binds only to PDGF-B chain, although Cheng and Mattson (1995) demonstrated the expression of both PDGF-a and -� receptors in cultured embryonic neurons in vitro. This view is consistent with previous studies that showed that PDGF-a receptor is expressed in glial cells or their pre cursors and not detected in neurons in embryonic and adult rodents (Pringle et aI., 1992; Yeh et aI., 1993) . In addition, several lines of evidence established ubiquitous neuronal expression of the -� receptors in the brain (Smits et aI., 1991; Hutchins and Jefferson, 1992; Iihara et aI., 1996a) .
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Another possible mechanism underlying the neuropro tective effects of PDGF-BB is prevention of the apop totic component of neuronal death. Recently, increasing evidence has indicated the involvement of apoptotic neu ronal death in the injury after both global and focal isch emia (Goto et aI., 1990; Shigeno et aI., 1990; Papas et aI., 1992; Heron et aI., 1993; MacManus et aI., 1993; Linnik et aI., 1993; Okamoto et aI., 1993; Roberts-Lewis et aI., 1993; Crumrine et aI., 1994; Li et aI., 1995; MacManus et aI., 1995; Du et aI., 1996) , although some contrasting results have been reported (Deshpande et aI., 1992; Dessi et aI., 1993) , as well as in other injury paradigms, such as neurotrophic factor withdrawal (Martin et aI., 1992) and excitotoxicity (Kure et aI., 1991) . Recently, it was re ported that PDGF prevents apoptosis after serum depri vation in PC 12 cells expressing the wild-type PDGF re ceptor through activation of phosphatidylinositol-3 ki nase (Yao and Cooper, 1995) . Further studies are required to conclude whether PDGF prevents an apop totic component of ischemic neuronal death after cere bral ischemia.
In conclusion, pretreatment with PDGF-BB, but not PDGF-AA, markedly inhibits delayed neuronal death af ter forebrain ischemia in rats. In contrast, posttreatment with PDGF-BB showed no significant neuroprotective effect after forebrain ischemia.
